SERPINE1 and type 2 diabetes mellitus: Troglitazone treatment in insulin-resistant lean or obese type 2 diabetes patients can lower PAI-1 concentrations and is associated with enhanced fibrinolytic activity linked to lower plasma insulin levels and improved glycemic control [20].